Four notes:
1. Total sales were up 5.8 percent year-over-year, according to a news release. This was largely driven by growing adoption of new products and increased procedural volume in the U.S.
2. U.S. cervical spine sales saw its sixth consecutive quarter of greater than 20 percent growth. Thhis was driven by C360 and Simplify cervical disc sales.
3. NuVasive expects 2023 net sales to grow 6 percent to 8 percent.
4. NuVasive reported a net loss of $1 million.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
